10-year follow-up of the GELA LNH 98.5 study
April 21, 2010
| Abstract Title: | 10-year follow-up of the GELA LNH 98.5 study |
| Authors: | Liviu Cheveresan |
| Affiliation: | University of Medicine and Pharmacy „Victor Babes”, Department of Clinical Hematology, Timisoara, Romania |
| Abstract text: | GELA LNH 98.5 study comparing R-CHOP with CHOP, established R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone) as the standard treatment for patients with diffuse large B-cell lymphoma (DLBCL). GELA LNH 98.5 study data after 2, 5 and 7 years of follow-up has previously been published. An overview of the data after 10 year follow up shows that the benefit observed in terms of EFS, DFS, PFS and OS after 2, 5 and 7 years of follow-up is still significant at 10 years. R-CHOP as first line DLBCL treatment improves patients long-term outcomes. |
| Keywords: | GELA, LNH |
| Presentation type: | Oral |
| Correspondence: | |
| Email: | alcionasasu@yahoo.com |
About The Author
